Treatment Discontinuation or Interruption in Pulmonary Arterial Hypertension

Shraddha Narechania, Heather Torbic, Adriano R. Tonelli

Research output: Contribution to journalReview articlepeer-review

10 Scopus citations


Pulmonary arterial hypertension (PAH) is a progressive disease, which can be potentially fatal. The management of a complex disease like PAH requires a multidisciplinary approach from a team consisting of physicians, nurses, social workers, and pharmacists. Adherence to PAH-specific therapy is one of the key factors in the management of this disease. Poor adherence to treatment is a common problem in PAH as it is in many chronic diseases. Management of medication interruptions is a challenge in patients with PAH that can lead to negative consequences. However, for most PAH-specific drugs, there are no clear guidelines on how to manage temporary or abrupt medication discontinuations. In this review, we summarized the available literature and provide suggestions on how to manage interruptions of PAH-specific therapies.

Original languageEnglish (US)
Pages (from-to)131-141
Number of pages11
JournalJournal of Cardiovascular Pharmacology and Therapeutics
Issue number2
StatePublished - Mar 1 2020
Externally publishedYes

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Cardiology and Cardiovascular Medicine
  • Pharmacology (medical)


Dive into the research topics of 'Treatment Discontinuation or Interruption in Pulmonary Arterial Hypertension'. Together they form a unique fingerprint.

Cite this